Fundz

Abvance Therapeutics secures seed funding to limit glucose lows. The company raised an undisclosed amount led by Zubi Capital for their insulin and glucagon combination product.

PRIVATEJun 27, 2025

Round Type

Seed

United StatesBiotechnologyBiopharma

Investors

Zubi Capital

Description

Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development of an insulin and glucagon combination product. The company has been in the process of developing this product for approximately 18 months.

Who else raised in Biopharma and Biotechnology around the same time

Companies in the same sectors as Abvance Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Entero Therapeutics raised $3M on August 9, 2025.
  • Lysoway Therapeutics raised $2.9M (Seed) on August 6, 2025.
  • Retension Pharmaceuticals raised $15M (Series B) on August 6, 2025.
  • DiaMedica Therapeutics raised $30M on July 23, 2025.
  • DiaMedica Therapeutics raised $30M (Post-IPO Equity) on July 21, 2025.
  • GenSight Biologics raised $580K (Seed) on July 17, 2025.

Who to call at Abvance Therapeutics, and when

A new round usually means Abvance Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Abvance Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Abvance Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Abvance Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Abvance Therapeutics

Location

United States

About

Abvance Therapeutics, Inc. is a privately held biotechnology company advancing novel glucagon-based therapies designed to integrate into the lived experience of diabetes care. Founded on research from Vanderbilt University and led by a team with expertise in diabetes therapeutics, drug development, and health technology.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Abvance Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Abvance Therapeutics's next move

See what Strategic adds

Abvance Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.